首页> 外文期刊>American Journal of Cancer Research > EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)
【24h】

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)

机译:非小细胞肺癌腺癌组织学中的EGFR突变发生率:系统评价和按种族划分的全球图谱(mutMapII)

获取原文
           

摘要

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC). Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/ADC, yet there is a lack of data for patients of other ethnicities. This review collated available data with the aim of creating a complete, global picture of EGFR mutation frequency in patients with NSCLC/ADC by ethnicity. Worldwide literature reporting EGFR mutation frequency in patients with NSCLC/ADC was reviewed, to create a map of the world populated with EGFR mutation frequency by country (a ‘global EGFR mutMap’). A total of 151 worldwide studies (n=33162 patients with NSCLC/ADC, of which 9749 patients had EGFR mutation-positive NSCLC/ADC) were included. There was substantial variation in EGFR mutation frequency between studies, even when grouped by geographic region or individual country. As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%]) and the lowest EGFR mutation frequency occurred in the Oceania NSCLC/ADC subgroup (12% [69/570; 4 studies; range 7%-36%]); however, comparisons between regions were limited due to the varying sizes of the patient populations studied. In all regional (geographic) subgroups where data were available, EGFR mutation frequency in NSCLC/ADC was higher in women compared with men, and in never-compared with ever-smokers. This review provides the foundation for a global map of EGFR mutation frequency in patients with NSCLC/ADC. The substantial lack of data from several large geographic regions of the world, notably Africa, the Middle East, Central Asia, and Central and South America, highlights a potential lack of routine mutation testing and the need for further investigations in these regions.
机译:在非小细胞肺癌(NSCLC)中,特别是在腺癌(ADC)组织学(NSCLC / ADC)肿瘤中,通常观察到表皮生长因子受体(EGFR)基因的突变。关于西方和亚洲NSCLC / ADC患者中EGFR突变患病率的可靠数据,但缺乏其他种族患者的数据。这篇综述对现有数据进行了整理,目的是通过种族对NSCLC / ADC患者的EGFR突变频率进行完整的全球描述。回顾了报道NSCLC / ADC患者中EGFR突变频率的全球文献,以绘制一张按国家/地区分布有EGFR突变频率的世界地图(“全球EGFR mutMap”)。纳入全球共151项研究(n = 33162例NSCLC / ADC患者,其中9749例EGFR突变阳性的NSCLC / ADC患者)。各个研究之间,即使按地理区域或单个国家分组,EGFR突变频率也存在很大差异。不出所料,亚太地区NSCLC / ADC亚组的EGFR突变频率最高(47%[5958/12819; 87个研究;范围20%-76%]),而EGFR突变频率最低的是大洋洲NSCLC / ADC亚组(12%[69/570; 4个研究;范围7%-36%]);但是,由于所研究患者人群的大小不同,区域之间的比较受到限制。在可获得数据的所有区域(地理)亚组中,女性的NSCLC / ADC中的EGFR突变频率高于男性,且从未有过吸烟者。该综述为NSCLC / ADC患者EGFR突变频率的全球图谱奠定了基础。来自世界几个大型地理区域的数据严重缺乏,特别是非洲,中东,中亚以及中南美洲,这突出表明可能缺乏常规的突变测试,并且需要在这些区域进行进一步的调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号